WO2004045446A1 - Controlled-dissolving polymeric device for the oral cavity - Google Patents

Controlled-dissolving polymeric device for the oral cavity Download PDF

Info

Publication number
WO2004045446A1
WO2004045446A1 PCT/US2003/036491 US0336491W WO2004045446A1 WO 2004045446 A1 WO2004045446 A1 WO 2004045446A1 US 0336491 W US0336491 W US 0336491W WO 2004045446 A1 WO2004045446 A1 WO 2004045446A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
controlled
oral care
water
care composition
Prior art date
Application number
PCT/US2003/036491
Other languages
French (fr)
Inventor
Neil J. Napolitano
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to JP2004553706A priority Critical patent/JP2006506436A/en
Priority to EP03783508A priority patent/EP1575444A1/en
Priority to AU2003290923A priority patent/AU2003290923A1/en
Priority to BR0316236-2A priority patent/BR0316236A/en
Priority to CA002505889A priority patent/CA2505889A1/en
Priority to MXPA05005153A priority patent/MXPA05005153A/en
Publication of WO2004045446A1 publication Critical patent/WO2004045446A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61CDENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
    • A61C19/00Dental auxiliary appliances
    • A61C19/06Implements for therapeutic treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61CDENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
    • A61C19/00Dental auxiliary appliances
    • A61C19/06Implements for therapeutic treatment
    • A61C19/063Medicament applicators for teeth or gums, e.g. treatment with fluorides
    • A61C19/066Bleaching devices; Whitening agent applicators for teeth, e.g. trays or strips
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/20Protective coatings for natural or artificial teeth, e.g. sealings, dye coatings or varnish
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61CDENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
    • A61C19/00Dental auxiliary appliances
    • A61C19/06Implements for therapeutic treatment
    • A61C19/08Implements for therapeutic treatment combined with anaesthetising implements

Definitions

  • This invention relates to compositions for the treatment of dentinal hypersensitivity and methods for treating dentinal hypersensitivity.
  • this invention relates to a sustained- or controlled-dissolution composition for the oral cavity that adheres to the natural teeth and/or gums, and which comprises agents capable of creating a physical barrier to dentinal hypersensitivity and/or which comprises pharmaceutical agents for the treatment of dentinal hypersensitivity.
  • Dentinal hypersensitivity is a temporary induced pain sensation produced when hypersensitive teeth are subjected to changes in temperature and/or pressure or to chemical action. Hypersensitivity may occur whenever attrition or abrasion exposes the dentin of a tooth, or when the tooth's finer root surface is exposed by periodontal disease.
  • Dentin is a bone-like material in teeth that is usually covered by enamel above the gum line and cementum below the gum line. The enamel or cementum may be removed through decay, injury, disease or other causes, thereby exposing the dentin to external stimuli in the mouth.
  • Dentin generally contains channels, called tubules, that allow material and energy transport between the exterior of the dentin and the interior of the tooth where the nerve is located.
  • the hydrodynamic theory suggests that exposure of these tubules to external stimuli can cause irritation of the nerve and lead to the discomfort of hypersensitivity.
  • the hydrodynamic theory f suggests that hypersensitivity may be treated by making the nerve in the tooth less sensitive to stimuli (called nerve desensitization), or by blocking or occluding the tubules to prevent or limit exposure of the nerve to external stimuli.
  • nerve desensitization makes the nerve in the tooth less sensitive to stimuli
  • blocking or occluding the tubules to prevent or limit exposure of the nerve to external stimuli.
  • Many attempts have been made to control dentinal hypersensitivity.
  • One approach is to reduce the excitability of the nerve in a sensitive tooth. This technique interferes with the ordinary triggering process of the nerve by altering the chemical environment of the nerve through the use of agents to make the nerve less sensitive.
  • nerve agents are generally referred to as “nerve agents” or “nerve desensitizing agents”.
  • ner agents By making the nerve less sensitive, the effect on the nerve of any external factors that are able to penetrate the tubules, is reduced.
  • potassium nitrate used in commercial dentifrices for sensitive teeth and discussed in U.S. Patent No. 3,863,006.
  • agents known as nerve desensitizing agents are found in the following U.S. patents: potassium salts such as potassium bicarbonate and potassium chloride, U.S. Patent Nos. 4,631,185 and 4,751,072; strontium and fluoride ions, U.S. Patent No. 4,990,327; and zinc and strontium ions, U.S. Patent No. 3,888,976.
  • Another approach to control dentinal hypersensitivity is the use of agents to fully or partially occlude tubules.
  • Tubule occluders serve to seal or block the dentin tubules thereby diminishing the effect of external stimuli such as changes in temperature, pressure, ionic gradients or contact with chemical irritants, as well as helping to reduce the flushing of potassium from the tubules by natural outward flow of dentinal fluid.
  • materials which are used as tubule blocking agents include materials having a particle size smaller than that of a dentin tubule for blocking the dentin tubules; and materials that can produce an agglomerate within the dentin tubules and/or form a precipitate that will deposit onto the dentinal surface.
  • tubule blocking agents are found in the following patents: charged polystyrene beads, U.S. Patent No. 5,211,939; apatite, U.S. Patent Nos. 4,634,589 and 4,710,372; a polyacrylic acid polymer having a typical molecular weight from about 450,000 to about 4,000,000, U.S. Patent No. 5,270,031 ; and water-soluble or water-swellable polyelectrolytes or salts thereof, U.S. Patent No. 4,362,713.
  • U.S. Patent No. 5,589,159 discloses the use of Laponite or hectorite clay to seal dentinal tubules.
  • 02/15809 discloses a synergistic combination of at least one tubule occluding agent and one nerve-desensitizing agent.
  • the oral care device of this invention achieves these goals by providing a sustained- or controlled-dissolution composition for the oral cavity that creates a barrier to painful stimuli associated with dentinal hypersensitivity.
  • the most significant problem in delivering any active to the dentin or nerve is the outward flow of dentinal fluid. Therefore, by creating a barrier over dentinal tubules, the dentinal fluid flow is reduced or eliminated. In addition to simply creating a barrier to pain, the reduction/elimination of fluid flow provides an enhanced environment for penetration of an active to the nerve.
  • Oral controlled-release delivery systems are well known in the pharmaceutical field and include the ability to maintain a desired level of medicament over a desired period of time.
  • the art describes free forms, such as sublingual tablets, troches and buccals.
  • other forms are designed to adhere to the oral mucosa and deliver an active pharmaceutical agent either directly into the oral mucosa, or into the saliva.
  • Ointments and other sticky adhering compositions have also been used.
  • the active ingredient in all these forms can act locally or systemically. Since the primary goal of these systems is to provide a drug active as opposed to providing a physical barrier to pain, none of the art systems suggest the instant invention.
  • U.S. Patent No. 4,059,686 describes a sustained-release pharmaceutical preparation for oral cavity adherence and administration to mucosal membranes characterized by being a mixture of a pharmacologically active agent, a pharmaceutical carrier, and sodium polyacrylate in conventional dosage form.
  • U.S. Patent No. 4,597,959 describes a cosmetic breath freshener composition in wafer form which is said to have slow release properties.
  • the composition includes a multiplicity of microencapsulated liquid droplets of flavoring material contained in an adhesive base.
  • U.S. Patent No. 4,772,470 discloses an oral bandage comprising a soft adhesive film comprising a mixture of polycarboxylic acid and/or a polycarboxylic acid anhydride and a vinyl acetate polymeric acid anhydride and a vinyl acetate polymer in a compatible state; and an oral preparation comprising such an oral bandage having incorporated therein a topical drug.
  • the oral bandage or preparation is reported to exhibit strong adhesion of long duration when applied to the oral mucosa or teeth.
  • U.S. Patent No. 4,876,092 describes a sheet-shaped adhesive preparation comprising an adhesive layer containing, as essential components, a carboxyvinyl polymer, a water-insoluble methacrylic copolymer, a polyhydric alcohol, and a pharmaceutically active agent, and a water-impermeable and water-insoluble carrier layer containing, as essential components, a pharmaceutically active, water- insoluble, film-forming high molecular weight compound and a plasticizer, which can adhere within the mucosal membranes of oral cavity over a period of time and release an active agent.
  • U.S. Patent Nos. 5,160,737 and 5,330,746 disclose a sustained-release liquid polymer or "varnish" composition comprising acrylic polymers (Eudragit® family of polymers) and a pharmaceutical agent.
  • the formulations are useful for preventing dental caries, periodontal disease, and tooth hypersensitivity by brushing or spraying the formulation onto the teeth and gingivae after which liquid polymer dries to a solid film.
  • European Patent Application 223 245 discloses a curable composition containing methacrylate monomers and a polymerization initiator for application to teeth and having the property of in-situ polymerization to form a hardened filler. Use of the filler in combination with an active agent releases the active agent from the hardened filler.
  • compositions would also be unsatisfactory for permitting substances such as mineralizers, or other systems that interact with saliva and oral flora to create an instant plug or an environment favorable for mineralization, since such actives require time to mature, or time to produce a desired effect, such as tooth whitening or pain relief during eating cold or salty foods.
  • a sustained- or controlled-dissolution oral care composition whose application is easy and uncomplicated, and which can create an immediate barrier to painful stimuli associated with dentinal hypersensitivity, and/or create a barrier to such pain by providing tubule occlusion to the site of pain.
  • the device is disintegrable over time and therefore does not require removal.
  • This invention relates to a sustained- or controlled-dissolution composition for the oral cavity that adheres to hard dental surfaces, such as teeth, as well as adjacent soft tissue, thereby forming a barrier to painful stimuli associated with dentinal hypersensitivity.
  • the composition of this invention may also contain an agent effective in reducing the pain associated with dentinal hypersensitivity. Dissolution of the composition is for a predetermined period of time and the agents, if present, at a predetermined concentration. The site of action of the agent is topical and local.
  • This invention also relates to a sustained- or controlled-dissolution composition capable of reacting with factors in the oral environment to form an insoluble barrier for occluding dentinal tubules.
  • the agents useful in creating an insoluble barrier are also useful in reducing dentin wear as a result of acid erosion or mechanical abrasion, such as during tooth brushing.
  • This invention is also further directed to suitable polymers and/or other barrier-producing compounds and/or cosmetically effective compounds for the oral device.
  • the device can comprise a single self-adherent release layer, or a dual layer comprising a non-adherent layer in combination with a separate adherent layer, or a multilayer structure.
  • the device comprises a multilayer structure, this enables incompatible compounds to remain separate until contact with heat and/or available water in the oral environment permits their interaction, or the oral environmental factors enable release of nerve desensitizers or barrier-producing compounds, including tubule occluders (e.g., stannous silicate), polymeric tubule occluders (e.g., octadecene/maleic anhydride copolymer, polyacrylic acid/Carbopol, and chitosan), mineralizers (e.g., a soluble calcium source in combination with a soluble phosphate source to produce calcium phosphate, a calcium releasing substrate, such as calcium silicate, hydroxyapatite, arginine carbonate or bioactive glass) or cosmetically relevant compounds.
  • tubule occluders e.g., stannous silicate
  • polymeric tubule occluders e.g., octadecene/maleic anhydride
  • This invention still further, relates to a method of making and using the sustained- or controlled-dissolution compositions described herein.
  • barrier means, a structure that hinders or prevents those factors associated with dentinal hypersensitivity from reaching the nerve, thereby reducing or eliminating the pain associated with dentinal hypersensitivity. Therefore, the term barrier suitably includes a solid polymeric oral care device or film that adheres to the teeth and surrounding soft tissue and/or a precipitate generated in situ, at the site of pain, and which occludes the dentinal tubules.
  • the composition may be in the form of an extruded or cast film which is applied directly to the desired site, forming a barrier which dissloves over time.
  • the composition may be in the form of a gel, paste, semi-solid balm, spray, and the like, all of which form a physical barrier in situ, which physical barrier dissloves over time.
  • the sustained- or controlled-dissolution composition of this invention is intended to prevent and/or treat dentinal hypersensitivity. This is achieved by (a) creating a physical barrier to painful stimuli at the site of sensitivity, (b) supplying agents to the site, which agents are capable of creating a physical barrier to painful stimuli, and/or (c) interacting with the oral environment, for example, saliva, to form a precipitate for occluding dentinal tubules.
  • the composition of this invention is capable of adhering to natural teeth or surrounding soft tissue and comprises at least one water-swellable or water-soluble polymer.
  • Suitable polymers include, but are not limited to, cellulose derivatives, such as ethyl cellulose (for example, Ethocel St- 10, manufactured by Dow Chemical Company, located in Midland, Michigan), hydroxypropylmethyl cellulose ("HPMC”) hydroxypropyl cellulose (“HPC”), carboxymethyl cellulose (“CMC”), polyethylene oxide (“Polyox®”), chitosan, starch, alginic acid and salts thereof, alkali metal salts of alkylvinylether/maleic acid or anhydride copolymer (“Gantrez®”), and mixtures thereof.
  • cellulose derivatives such as ethyl cellulose (for example, Ethocel St- 10, manufactured by Dow Chemical Company, located in Midland, Michigan), hydroxypropylmethyl cellulose (“HPMC”) hydroxypropyl cellulose (“HPC”), carboxymethyl
  • the oral care composition may be in the form of an extruded film or cast/evaporated film.
  • the oral care composition may be in the form of a gel, paste, spray, semi-solid balm, and the like, all of which form a physical barrier upon application to the site of pain.
  • the oral care composition described herein is capable of dissolving over time.
  • the time frame within which the composition dissolves depends upon the desired use. So, for example, the composition can be formulated for "spot relief, that is where the dissolution time is from about 1 to 5 minutes. Or, the composition can be formulated for more sustained dissolution, for example to correspond to an event such as a meal, that is where the dissolution time is from about 30 to 60 minutes. Further, the composition can be formulated for long term dissolution, for example to provide pain relief for an entire day. In order to achieve varying dissolution times, the skilled artisan would manipulate the polymers used in the composition. For example, HPC dissolves much slower than HPMC.
  • the composition of the invention may be used as a barrier to the painful stimuli associated with dentinal hypersensitivity.
  • a person sensitive to food items will apply the oral care composition claimed herein to the area of sensitivity just prior to ingesting such food, for example, ice cream.
  • the instant composition would serve as a barrier to the cold, as well as air stimuli, and slowly dissolve over time, or at least in time for the meal to be completed.
  • the instant composition can also contain a nerve desensitizer which acts at the site of pain while concurrently providing a physical barrier to pain.
  • a nerve desensitizer which acts at the site of pain while concurrently providing a physical barrier to pain.
  • the composition provides the immediate pain relief benefit of a physical barrier, while also providing the prolonged benefit of a nerve desensitizer, acting at the site of pain even after the composition has dissolved.
  • Suitable nerve desensitizing agents include, but are not limited to, potassium salts, for example, potassium nitrate, potassium chloride, potassium bicarbonate, and potassium citrate, strontium salts, for example, strontium chloride, strontium acetate, strontium nitrate, and strontium fluoride, and a combination of zinc and strontium ions, or mixtures thereof.
  • the nerve-desensitizing agent is incorporated in the composition in a desensitizing effective amount. This will vary depending on the particular shape and thickness of the solid oral care composition used.
  • the nerve agent will be present in an amount of about 0.1 to 15 wt.%, preferably from about 0.3 to 10 wt.%, and most preferably from about 2 to 8 wt.%.
  • the instant composition can also create a physical barrier by being comprised of agents which are capable of occluding the dentinal tubules.
  • agents capable of occluding the dentinal tubules can do so by reacting with the oral environment to create a precipitate which occludes the tubules through a process called mineralization.
  • agents which occlude dentinal tubules by mineralization include, but are not limited to, a soluble calcium source in combination with a soluble phosphate source to produce calcium phosphate, a calcium releasing substrate, such as calcium silicate, hydroxyapatite, arginine carbonate or bioactive glass. Mineralization can occur when the oral care composition is exposed to saliva containing calcium and/or phosphate.
  • Agents capable of occluding dentinal tubules can also do so without mineralization.
  • One way is by forming a non-mineral precipitate, for example, by "salting-out" a compound precipitate capable of occluding the tubules. This can be done by manipulating the pH of the composition when it encounters the oral environment, or when the composition is exposed to ions in the saliva.
  • agents which occlude dentinal tubules without mineralization are also included within the scope of this invention and include, but are not limited to, inorganic tubule occluders, for example, stannous silicate, and polymer tubule occluders, for example, sodium alginate, octadecene/maleic anhydride copolymer, polyacrylic acid/ Carbopol, and chitosan.
  • inorganic tubule occluders for example, stannous silicate
  • polymer tubule occluders for example, sodium alginate, octadecene/maleic anhydride copolymer, polyacrylic acid/ Carbopol, and chitosan.
  • Suitable occluders can be found in WO 02/15809, incorporated herein by reference.
  • the tubule blocking agent/ occluder is incorporated in this composition in a desensitizing tubule occluding effective amount. The amount will vary depending on the particular shape and thickness of the solid oral care composition used.
  • the tubule blocking agent will be in an amount of about 0.1 to 15 wt.%, preferably from about 0.4 to 10% and most preferably from about 2 to 8 wt.%.
  • Phosphate, coco and alike soaps such as MAPS (Rhodia) may be incorporated to further enhance the physical occlusion. Larger amounts of the tubule blocking agent can also be employed if desired.
  • composition of this invention is also suitable for use in preventing the hypersensitivity associated with tooth whitening preparations. Further uses of the instant compositions include, but are not limited to, treating gingivitis and preventing caries. By creating a physical barrier, the instant composition prevents exposure of the sensitive areas to irritants, food acid, bacteria and other factors in the oral environment which cause sensitivity, disease or pain.
  • sustained- or controlled-dissolution compositions containing the desensitizing attributes of the present invention may contain additional ingredients typically incorporated into oral care compositions. Suitable ingredients include, without limitation, a fluoride source, flavoring agents, humectants, binders and sweetening agents.
  • Humectants contemplated for use in these compositions include, but are not limited to, polyols, such as glycerol, sorbitol, polyethylene glycols, propylene glycol, hydrogenated partially hydrolyzed polysaccharides, and the like.
  • the humectants are generally present in amounts of from 0 to 80 wt.%.
  • Thickeners suitable for use in the invention, for example silica, may be present at a level from about 0 to 50 wt.%.
  • Binders suitable for use in the compositions of the invention include, but are not limited to, hydroxyethyl cellulose, and hydroxypropyl cellulose, as well as xanthan gums, Iris moss and gum tragacaiith. Binders may be present in the amount from 0.01 to 100 wt.%o. Sweeteners suitable for use, e.g., saccharin, may be present at levels of about 0 to 5 wt.%.
  • Fluoride sources commonly used in oral health care compositions such as sodium fluoride, stannous fluoride, sodium monofluorophosphate, zinc ammonium fluoride, tin ammonium fluoride, calcium fluoride, a ine fluoride, and cobalt ammonium fluoride may be included for delivering anti-caries benefit.
  • fluoride ions are typically provided at a level of from 0 to 1500 ppm, preferably 50 to 1500 ppm, although higher levels up to about 3000 ppm may be used.
  • Suitable flavors are usually included in low amounts, such as from 0 to about 5 wt.%).
  • Dyes/colorants suitable for oral health care compositions i.e., FD & C Blue #1, FD & C Yellow #10, FD & C Red #40, etc., may be employed as well.
  • the instant composition may also include other pharmaceutically or cosmetically active agents requiring local application, for example, local anesthetics, for example, eugenol, dibucaine hydrochloride, dibucaine, lidocaine hydrochloride, lidocaine, bezocaine, p-buthylaminobenzoic acid 2-(di-ethylamine ethyl ester hydrochloride, procaine hydrochloride, tetracaine hydrochloride, chloroprocaine hydrochloride, oxyprocaine, hydrochloride, mepivacaine, cocaine hydrochloride, and piperocaine hydrochloride, tooth whitening agents, for example, sodium tripolyphosphate, urea peroxide, hydrogen peroxide, and peroxide releasing agents, such as perborate or percarbonate.
  • local anesthetics for example, eugenol, dibucaine hydrochloride, dibucaine, lidocaine hydrochloride,
  • the oral care device of this invention can comprise any shape or thickness suitable for application to a discreet area in the mouth.
  • the oral care device may be a square, rectangle, circle, semi-circle, or other geometry, consideration being given to the area to be covered, and the desire to reduce the "foreign feeling" of having the device in the mouth.
  • the oral care device is 0.1-50 mm thick, preferably 3- 5mm, depending upon the structure (e.g., single or multi-layered), the desired dissolution time, and the presence of active ingredients.
  • the oral care device can be multi-layered with incompatible materials in separate layers (such as zinc and/or calcium and phosphate and/or silicate), and/or one adhesive layer, the other non-adhesive (so as to stick to gingiva and teeth but not the cheek or tongue).
  • incompatible materials such as zinc and/or calcium and phosphate and/or silicate
  • one adhesive layer such as zinc and/or calcium and phosphate and/or silicate
  • the other non-adhesive such as to stick to gingiva and teeth but not the cheek or tongue.
  • the composition can be administered in the form of a spray, paste, gel, semi-solid balm, and the like. If delivered in one of these forms, the composition will form a film upon contact with the tooth surface creating a physical barrier to painful stimuli, and thereafter dissolve over time.
  • Example 1 illustrates the use of a cationic polymer for making a composition of the invention, which polymer is compatible with other cationic ingredients for inclusion in the composition, for example, stannous ions, zinc ions and cetylpyrridinium chloride (“CPC").
  • CPC cetylpyrridinium chloride
  • Example 2 illustrates the use of non-ionic polymer for making a composition of the invention.
  • Example 3 illustrates the use of anionic polymers for making a composition of the invention, which polymer is compatible with other anionic ingredients for inclusion in the composition, for example, alginic acid, Polyox®, and CMC.
  • Example 4 illustrates a formulation of the invention useful for preventing the pain associated with tooth whitening.
  • the above films are made by dissolving the ingredients in water with suitable agitation, and pouring the mixture onto a casting plate.
  • the liquid is dried by air at room temperature, or in a vacuum oven at elevated temperatures.
  • the reactive agents can be added after some drying of the composition occurs, in order to prevent reaction in solution.
  • the film can then be cut in any geometry desired.
  • Examples 5 through 7 illustrate extruded films that are made according to this invention. Conventional techniques l ⁇ iown in the art for making extruded films can be applied to the instant invention.
  • Example 8 illustrates a two-layer system according to the invention.
  • Layer 1 :
  • Example 9 Illustrates a film forming paste.
  • Carbopol was dispersed in the ethanol. Glycerol was added and mixture stirred until material thickens. Ethocel was added. A second mixture was prepared containing the molten petrolatum, PEG 400, clove oil and the silica dispersed in the mixture. To the petrolatum silica dispersion was added the ethocel mixture with stirring. And blend thoroughly until mixture was homogeneous. Cooled gel was packed into tubes. This material sticks readily to wet surfaces.
  • Example 10 Illustrates a film forming gel. Ethyl cellulose was dispersed in the ethanol. A second mixture containing the molten petrolatum, mineral oil, clove oil and the silica dispersed therein, was prepared. To the petrolatum silica dispersion was added the ethocel mixture with stirring. The mixture was blended thoroughly until it was homogeneous. This mixture can be packed in tubes or pen applicators and spread on teeth with a finger or brush.
  • Example 11 Illustrates a film forming spray.
  • Ethyl cellulose was dispersed in the ethanol and triethyl citrate.
  • a second mixture was prepared containing the molten petrolatum, mineral oil and clove oil and the silica dispersed in it.
  • To the petrolatum mixture was added the ethyl cellulose mixture with stirring. This mixture was blended thoroughly until mixture was homogeneous. The mixture can be sprayed onto wet surfaces from a pump spray.

Abstract

The invention is directed to a solid, controlled-dissolution composition for the oral cavity that adheres to hard dental surfaces, such as natural teeth and the surrounding soft tissue, and which creates a physical barrier to painful stimuli associated with dentinal hypersensivity.

Description

CONTROLLED-DISSOLVTNG POLYMERIC DEVICE FOR THE ORAL
CAVITY
FIELD OF THE INVENTION
This invention relates to compositions for the treatment of dentinal hypersensitivity and methods for treating dentinal hypersensitivity. In particular, this invention relates to a sustained- or controlled-dissolution composition for the oral cavity that adheres to the natural teeth and/or gums, and which comprises agents capable of creating a physical barrier to dentinal hypersensitivity and/or which comprises pharmaceutical agents for the treatment of dentinal hypersensitivity.
BACKGROUND OF INVENTION
Dentinal hypersensitivity is a temporary induced pain sensation produced when hypersensitive teeth are subjected to changes in temperature and/or pressure or to chemical action. Hypersensitivity may occur whenever attrition or abrasion exposes the dentin of a tooth, or when the tooth's finer root surface is exposed by periodontal disease. Dentin is a bone-like material in teeth that is usually covered by enamel above the gum line and cementum below the gum line. The enamel or cementum may be removed through decay, injury, disease or other causes, thereby exposing the dentin to external stimuli in the mouth. Dentin generally contains channels, called tubules, that allow material and energy transport between the exterior of the dentin and the interior of the tooth where the nerve is located.
One theory of dentinal hypersensitivity, called the hydrodynamic theory, suggests that exposure of these tubules to external stimuli can cause irritation of the nerve and lead to the discomfort of hypersensitivity. The hydrodynamic theory f suggests that hypersensitivity may be treated by making the nerve in the tooth less sensitive to stimuli (called nerve desensitization), or by blocking or occluding the tubules to prevent or limit exposure of the nerve to external stimuli. Many attempts have been made to control dentinal hypersensitivity. One approach is to reduce the excitability of the nerve in a sensitive tooth. This technique interferes with the ordinary triggering process of the nerve by altering the chemical environment of the nerve through the use of agents to make the nerve less sensitive. These agents are generally referred to as "nerve agents" or "nerve desensitizing agents". By making the nerve less sensitive, the effect on the nerve of any external factors that are able to penetrate the tubules, is reduced. Any nerve desensitizing agent that is a neuroactive substance, i.e., any ion or salt that has a pain reducing or analgesic activity, is suitable for use in the composition of the present invention.
The most well-known agent for this purpose is potassium nitrate, used in commercial dentifrices for sensitive teeth and discussed in U.S. Patent No. 3,863,006. Examples of other agents known as nerve desensitizing agents are found in the following U.S. patents: potassium salts such as potassium bicarbonate and potassium chloride, U.S. Patent Nos. 4,631,185 and 4,751,072; strontium and fluoride ions, U.S. Patent No. 4,990,327; and zinc and strontium ions, U.S. Patent No. 3,888,976. Another approach to control dentinal hypersensitivity, as discussed above with regard to the hydrodynamic theory, is the use of agents to fully or partially occlude tubules. Tubule occluders serve to seal or block the dentin tubules thereby diminishing the effect of external stimuli such as changes in temperature, pressure, ionic gradients or contact with chemical irritants, as well as helping to reduce the flushing of potassium from the tubules by natural outward flow of dentinal fluid. Examples of materials which are used as tubule blocking agents include materials having a particle size smaller than that of a dentin tubule for blocking the dentin tubules; and materials that can produce an agglomerate within the dentin tubules and/or form a precipitate that will deposit onto the dentinal surface. Specific examples of such "tubule blocking agents" are found in the following patents: charged polystyrene beads, U.S. Patent No. 5,211,939; apatite, U.S. Patent Nos. 4,634,589 and 4,710,372; a polyacrylic acid polymer having a typical molecular weight from about 450,000 to about 4,000,000, U.S. Patent No. 5,270,031 ; and water-soluble or water-swellable polyelectrolytes or salts thereof, U.S. Patent No. 4,362,713. In addition, U.S. Patent No. 5,589,159 discloses the use of Laponite or hectorite clay to seal dentinal tubules.
PCT Patent Application WO 00/042981 discloses a different mode of action wherein a composition of two different desensitizing agents (stannous fluoride and potassium nitrate) is separated in a dual phase dispensing unit. These agents are separated in the disclosed compositions to enhance their stability. Further, WO
02/15809 discloses a synergistic combination of at least one tubule occluding agent and one nerve-desensitizing agent.
While these approaches have achieved a certain level of success, there is a need for a portable and inconspicuous treatment for tooth sensitivity and the pain associated therewith, that is local in application providing fast acting relief over a discreet, but extended time period. The oral care device of this invention achieves these goals by providing a sustained- or controlled-dissolution composition for the oral cavity that creates a barrier to painful stimuli associated with dentinal hypersensitivity.
The most significant problem in delivering any active to the dentin or nerve is the outward flow of dentinal fluid. Therefore, by creating a barrier over dentinal tubules, the dentinal fluid flow is reduced or eliminated. In addition to simply creating a barrier to pain, the reduction/elimination of fluid flow provides an enhanced environment for penetration of an active to the nerve.
Oral controlled-release delivery systems are well known in the pharmaceutical field and include the ability to maintain a desired level of medicament over a desired period of time. The art describes free forms, such as sublingual tablets, troches and buccals. In addition to non-attached oral sustained- or release forms, other forms are designed to adhere to the oral mucosa and deliver an active pharmaceutical agent either directly into the oral mucosa, or into the saliva. Ointments and other sticky adhering compositions have also been used. The active ingredient in all these forms can act locally or systemically. Since the primary goal of these systems is to provide a drug active as opposed to providing a physical barrier to pain, none of the art systems suggest the instant invention.
U.S. Patent No. 4,059,686 describes a sustained-release pharmaceutical preparation for oral cavity adherence and administration to mucosal membranes characterized by being a mixture of a pharmacologically active agent, a pharmaceutical carrier, and sodium polyacrylate in conventional dosage form.
U.S. Patent No. 4,597,959 describes a cosmetic breath freshener composition in wafer form which is said to have slow release properties. The composition includes a multiplicity of microencapsulated liquid droplets of flavoring material contained in an adhesive base.
U.S. Patent No. 4,772,470 discloses an oral bandage comprising a soft adhesive film comprising a mixture of polycarboxylic acid and/or a polycarboxylic acid anhydride and a vinyl acetate polymeric acid anhydride and a vinyl acetate polymer in a compatible state; and an oral preparation comprising such an oral bandage having incorporated therein a topical drug. The oral bandage or preparation is reported to exhibit strong adhesion of long duration when applied to the oral mucosa or teeth.
U.S. Patent No. 4,876,092 describes a sheet-shaped adhesive preparation comprising an adhesive layer containing, as essential components, a carboxyvinyl polymer, a water-insoluble methacrylic copolymer, a polyhydric alcohol, and a pharmaceutically active agent, and a water-impermeable and water-insoluble carrier layer containing, as essential components, a pharmaceutically active, water- insoluble, film-forming high molecular weight compound and a plasticizer, which can adhere within the mucosal membranes of oral cavity over a period of time and release an active agent.
U.S. Patent Nos. 5,160,737 and 5,330,746 disclose a sustained-release liquid polymer or "varnish" composition comprising acrylic polymers (Eudragit® family of polymers) and a pharmaceutical agent. The formulations are useful for preventing dental caries, periodontal disease, and tooth hypersensitivity by brushing or spraying the formulation onto the teeth and gingivae after which liquid polymer dries to a solid film. European Patent Application 223 245 discloses a curable composition containing methacrylate monomers and a polymerization initiator for application to teeth and having the property of in-situ polymerization to form a hardened filler. Use of the filler in combination with an active agent releases the active agent from the hardened filler. Published U.S. application US 2001/0024657 Al, describes a sustained- release solid composition that adheres to hard dentinal surfaces, such as teeth and dentures, and which contains a pharmaceutically active agent. Polyacrylic or polymethacrylic polymers are disclosed as particularly useful in creating an effective controlled-release drug delivery system. Other known preparations usually comprise components which are quickly soluble or disintegrable within the mouth. The pharmaceutically active agents contained in these preparations are mostly swallowed without being absorbed through the mucous membrane in the oral cavity, making these preparations unsatisfactory as sustained- or controlled-release preparations, or as a physical barrier to pain. These known compositions would also be unsatisfactory for permitting substances such as mineralizers, or other systems that interact with saliva and oral flora to create an instant plug or an environment favorable for mineralization, since such actives require time to mature, or time to produce a desired effect, such as tooth whitening or pain relief during eating cold or salty foods.
Accordingly, there is a need for a sustained- or controlled-dissolution oral care composition whose application is easy and uncomplicated, and which can create an immediate barrier to painful stimuli associated with dentinal hypersensitivity, and/or create a barrier to such pain by providing tubule occlusion to the site of pain. The device is disintegrable over time and therefore does not require removal. SUMMARY OF THE INVENTION
This invention relates to a sustained- or controlled-dissolution composition for the oral cavity that adheres to hard dental surfaces, such as teeth, as well as adjacent soft tissue, thereby forming a barrier to painful stimuli associated with dentinal hypersensitivity. The composition of this invention may also contain an agent effective in reducing the pain associated with dentinal hypersensitivity. Dissolution of the composition is for a predetermined period of time and the agents, if present, at a predetermined concentration. The site of action of the agent is topical and local. This invention also relates to a sustained- or controlled-dissolution composition capable of reacting with factors in the oral environment to form an insoluble barrier for occluding dentinal tubules. In addition to occluding tubules, the agents useful in creating an insoluble barrier are also useful in reducing dentin wear as a result of acid erosion or mechanical abrasion, such as during tooth brushing. This invention is also further directed to suitable polymers and/or other barrier-producing compounds and/or cosmetically effective compounds for the oral device. The device can comprise a single self-adherent release layer, or a dual layer comprising a non-adherent layer in combination with a separate adherent layer, or a multilayer structure. If the device comprises a multilayer structure, this enables incompatible compounds to remain separate until contact with heat and/or available water in the oral environment permits their interaction, or the oral environmental factors enable release of nerve desensitizers or barrier-producing compounds, including tubule occluders (e.g., stannous silicate), polymeric tubule occluders (e.g., octadecene/maleic anhydride copolymer, polyacrylic acid/Carbopol, and chitosan), mineralizers (e.g., a soluble calcium source in combination with a soluble phosphate source to produce calcium phosphate, a calcium releasing substrate, such as calcium silicate, hydroxyapatite, arginine carbonate or bioactive glass) or cosmetically relevant compounds.
This invention still further, relates to a method of making and using the sustained- or controlled-dissolution compositions described herein.
DETAILED DESCRIPTION OF THE INVENTION
The term "barrier" as used herein at all occurrences means, a structure that hinders or prevents those factors associated with dentinal hypersensitivity from reaching the nerve, thereby reducing or eliminating the pain associated with dentinal hypersensitivity. Therefore, the term barrier suitably includes a solid polymeric oral care device or film that adheres to the teeth and surrounding soft tissue and/or a precipitate generated in situ, at the site of pain, and which occludes the dentinal tubules.
In the case of a device or film, the composition may be in the form of an extruded or cast film which is applied directly to the desired site, forming a barrier which dissloves over time. In an alternative embodiment, the composition may be in the form of a gel, paste, semi-solid balm, spray, and the like, all of which form a physical barrier in situ, which physical barrier dissloves over time.
The sustained- or controlled-dissolution composition of this invention is intended to prevent and/or treat dentinal hypersensitivity. This is achieved by (a) creating a physical barrier to painful stimuli at the site of sensitivity, (b) supplying agents to the site, which agents are capable of creating a physical barrier to painful stimuli, and/or (c) interacting with the oral environment, for example, saliva, to form a precipitate for occluding dentinal tubules.
The composition of this invention is capable of adhering to natural teeth or surrounding soft tissue and comprises at least one water-swellable or water-soluble polymer. Suitable polymers include, but are not limited to, cellulose derivatives, such as ethyl cellulose (for example, Ethocel St- 10, manufactured by Dow Chemical Company, located in Midland, Michigan), hydroxypropylmethyl cellulose ("HPMC") hydroxypropyl cellulose ("HPC"), carboxymethyl cellulose ("CMC"), polyethylene oxide ("Polyox®"), chitosan, starch, alginic acid and salts thereof, alkali metal salts of alkylvinylether/maleic acid or anhydride copolymer ("Gantrez®"), and mixtures thereof.
Suitably, the oral care composition may be in the form of an extruded film or cast/evaporated film. In addition, the oral care composition may be in the form of a gel, paste, spray, semi-solid balm, and the like, all of which form a physical barrier upon application to the site of pain.
The oral care composition described herein is capable of dissolving over time. The time frame within which the composition dissolves depends upon the desired use. So, for example, the composition can be formulated for "spot relief, that is where the dissolution time is from about 1 to 5 minutes. Or, the composition can be formulated for more sustained dissolution, for example to correspond to an event such as a meal, that is where the dissolution time is from about 30 to 60 minutes. Further, the composition can be formulated for long term dissolution, for example to provide pain relief for an entire day. In order to achieve varying dissolution times, the skilled artisan would manipulate the polymers used in the composition. For example, HPC dissolves much slower than HPMC. By varying the concentration of one or more of these polymers in the composition, one of skill in the art could formulate a product that dissolves at varying rates of time. The sustained- or controlled-dissolution of this composition is essential to its performance as a barrier to painful stimuli, and/or, as a composition capable of providing a tubule-occluding barrier to painful stimuli directly to the site of pain. For treating hypersensitivity, the composition of the invention may be used as a barrier to the painful stimuli associated with dentinal hypersensitivity. For example, a person sensitive to food items will apply the oral care composition claimed herein to the area of sensitivity just prior to ingesting such food, for example, ice cream. The instant composition would serve as a barrier to the cold, as well as air stimuli, and slowly dissolve over time, or at least in time for the meal to be completed.
In addition to providing a physical barrier to painful stimuli associated with dentinal hypersensitivity, the instant composition can also contain a nerve desensitizer which acts at the site of pain while concurrently providing a physical barrier to pain. In this way, the composition provides the immediate pain relief benefit of a physical barrier, while also providing the prolonged benefit of a nerve desensitizer, acting at the site of pain even after the composition has dissolved.
Suitable nerve desensitizing agents include, but are not limited to, potassium salts, for example, potassium nitrate, potassium chloride, potassium bicarbonate, and potassium citrate, strontium salts, for example, strontium chloride, strontium acetate, strontium nitrate, and strontium fluoride, and a combination of zinc and strontium ions, or mixtures thereof.
The nerve-desensitizing agent is incorporated in the composition in a desensitizing effective amount. This will vary depending on the particular shape and thickness of the solid oral care composition used. Suitably, the nerve agent will be present in an amount of about 0.1 to 15 wt.%, preferably from about 0.3 to 10 wt.%, and most preferably from about 2 to 8 wt.%.
In addition to serving as a physical barrier to painful stimuli associated with dentinal hypersensitivity, the instant composition can also create a physical barrier by being comprised of agents which are capable of occluding the dentinal tubules. Agents capable of occluding the dentinal tubules can do so by reacting with the oral environment to create a precipitate which occludes the tubules through a process called mineralization. Suitably, agents which occlude dentinal tubules by mineralization are included in the scope of this invention and include, but are not limited to, a soluble calcium source in combination with a soluble phosphate source to produce calcium phosphate, a calcium releasing substrate, such as calcium silicate, hydroxyapatite, arginine carbonate or bioactive glass. Mineralization can occur when the oral care composition is exposed to saliva containing calcium and/or phosphate.
Agents capable of occluding dentinal tubules can also do so without mineralization. One way is by forming a non-mineral precipitate, for example, by "salting-out" a compound precipitate capable of occluding the tubules. This can be done by manipulating the pH of the composition when it encounters the oral environment, or when the composition is exposed to ions in the saliva. Suitably, agents which occlude dentinal tubules without mineralization are also included within the scope of this invention and include, but are not limited to, inorganic tubule occluders, for example, stannous silicate, and polymer tubule occluders, for example, sodium alginate, octadecene/maleic anhydride copolymer, polyacrylic acid/ Carbopol, and chitosan.
Suitable occluders can be found in WO 02/15809, incorporated herein by reference. The tubule blocking agent/ occluder is incorporated in this composition in a desensitizing tubule occluding effective amount. The amount will vary depending on the particular shape and thickness of the solid oral care composition used.
Suitably, the tubule blocking agent will be in an amount of about 0.1 to 15 wt.%, preferably from about 0.4 to 10% and most preferably from about 2 to 8 wt.%.
Phosphate, coco and alike soaps such as MAPS (Rhodia), may be incorporated to further enhance the physical occlusion. Larger amounts of the tubule blocking agent can also be employed if desired.
The composition of this invention is also suitable for use in preventing the hypersensitivity associated with tooth whitening preparations. Further uses of the instant compositions include, but are not limited to, treating gingivitis and preventing caries. By creating a physical barrier, the instant composition prevents exposure of the sensitive areas to irritants, food acid, bacteria and other factors in the oral environment which cause sensitivity, disease or pain.
The sustained- or controlled-dissolution compositions containing the desensitizing attributes of the present invention may contain additional ingredients typically incorporated into oral care compositions. Suitable ingredients include, without limitation, a fluoride source, flavoring agents, humectants, binders and sweetening agents.
Humectants contemplated for use in these compositions include, but are not limited to, polyols, such as glycerol, sorbitol, polyethylene glycols, propylene glycol, hydrogenated partially hydrolyzed polysaccharides, and the like. The humectants are generally present in amounts of from 0 to 80 wt.%. Thickeners suitable for use in the invention, for example silica, may be present at a level from about 0 to 50 wt.%.
Binders suitable for use in the compositions of the invention include, but are not limited to, hydroxyethyl cellulose, and hydroxypropyl cellulose, as well as xanthan gums, Iris moss and gum tragacaiith. Binders may be present in the amount from 0.01 to 100 wt.%o. Sweeteners suitable for use, e.g., saccharin, may be present at levels of about 0 to 5 wt.%.
Fluoride sources commonly used in oral health care compositions, such as sodium fluoride, stannous fluoride, sodium monofluorophosphate, zinc ammonium fluoride, tin ammonium fluoride, calcium fluoride, a ine fluoride, and cobalt ammonium fluoride may be included for delivering anti-caries benefit. If present, fluoride ions are typically provided at a level of from 0 to 1500 ppm, preferably 50 to 1500 ppm, although higher levels up to about 3000 ppm may be used.
Suitable flavors are usually included in low amounts, such as from 0 to about 5 wt.%). Dyes/colorants suitable for oral health care compositions, i.e., FD & C Blue #1, FD & C Yellow #10, FD & C Red #40, etc., may be employed as well.
Suitably, the instant composition may also include other pharmaceutically or cosmetically active agents requiring local application, for example, local anesthetics, for example, eugenol, dibucaine hydrochloride, dibucaine, lidocaine hydrochloride, lidocaine, bezocaine, p-buthylaminobenzoic acid 2-(di-ethylamine ethyl ester hydrochloride, procaine hydrochloride, tetracaine hydrochloride, chloroprocaine hydrochloride, oxyprocaine, hydrochloride, mepivacaine, cocaine hydrochloride, and piperocaine hydrochloride, tooth whitening agents, for example, sodium tripolyphosphate, urea peroxide, hydrogen peroxide, and peroxide releasing agents, such as perborate or percarbonate. Also included may be pH adjusting agents; anti- caries agents such as calcium glycerophosphate, sodium trimetaphosphate; anti- staining compounds such as silicone polymers, plant extracts and mixtures thereof. The oral care device of this invention can comprise any shape or thickness suitable for application to a discreet area in the mouth. The oral care device may be a square, rectangle, circle, semi-circle, or other geometry, consideration being given to the area to be covered, and the desire to reduce the "foreign feeling" of having the device in the mouth. Suitably, the oral care device is 0.1-50 mm thick, preferably 3- 5mm, depending upon the structure (e.g., single or multi-layered), the desired dissolution time, and the presence of active ingredients. Suitably, the oral care device can be multi-layered with incompatible materials in separate layers (such as zinc and/or calcium and phosphate and/or silicate), and/or one adhesive layer, the other non-adhesive (so as to stick to gingiva and teeth but not the cheek or tongue).
In an alternative embodiment, the composition can be administered in the form of a spray, paste, gel, semi-solid balm, and the like. If delivered in one of these forms, the composition will form a film upon contact with the tooth surface creating a physical barrier to painful stimuli, and thereafter dissolve over time.
The invention will now be illustrated in greater detail with reference to the following examples, but it should be understood that these are not intended to limit the present invention.
EXAMPLES.
Example 1: illustrates the use of a cationic polymer for making a composition of the invention, which polymer is compatible with other cationic ingredients for inclusion in the composition, for example, stannous ions, zinc ions and cetylpyrridinium chloride ("CPC").
INGREDIENT %w/w
Chitosan 2.0
Glycerin 0.5
SnF2 90ppm
Zn lactate 1.0
Lactic acid 2.0
Sn gluconate 0.5
CPC 0.2
Water Q.S.
Example 2: illustrates the use of non-ionic polymer for making a composition of the invention.
INGREDIENT %w/w
HEC 0.25
Water Q.S.
HPC 4.50
HPMC 0.25
Triclosan 0.02 Example 3: illustrates the use of anionic polymers for making a composition of the invention, which polymer is compatible with other anionic ingredients for inclusion in the composition, for example, alginic acid, Polyox®, and CMC.
INGREDIENT %w/w
Alginic acid 1.0
HPC 3.0
Polyox® 0.5
CMC 0.3
Na/Ca Gantrez 0.3
Silicon Dioxide 0.1
PEG 600 0.5
SrCl2 0.6
Water Q.S.
Example 4: illustrates a formulation of the invention useful for preventing the pain associated with tooth whitening.
INGREDIENT %w/w HEC 0.25
Water Q.S.
Silaceous mineralizer 1.00
HPC 4.50
HPMC 0.25 Urea peroxide 0.80
The above films are made by dissolving the ingredients in water with suitable agitation, and pouring the mixture onto a casting plate. The liquid is dried by air at room temperature, or in a vacuum oven at elevated temperatures. For those compositions with reactive agents, such as urea peroxide, the reactive agents can be added after some drying of the composition occurs, in order to prevent reaction in solution. The film can then be cut in any geometry desired.
Examples 5 through 7 illustrate extruded films that are made according to this invention. Conventional techniques lαiown in the art for making extruded films can be applied to the instant invention. Example 5:
INGREDIENT %w/w
Polylysine 10.0
HPC Q.S.
Chitosan 5.0
Citric acid 5.0
Glycerin 3.0
Chlorhexidine 0.1
Example 6:
INGREDIENT %>w/w
HPC 80
SiO2 2.5
HEC 4.0
HPMC 1.5
PEG 1450 4.0
Urea peroxide 8.0
Flavor 0.1
Example 7:
INGREDIENT %w/w
Polyox 45.0
CMC 3.0
HPC 5.0
Na/Ca Gantrez 15.0
Silicon Dioxide 3.0
PEG 600 0.1
Starch 5.0
KNO3 3.8
Water 25.0 Example 8: illustrates a two-layer system according to the invention. Layer 1:
INGREDIENT %w/w
SnF2 500ppm
SnCl2 1.0
HPC 90.0
Water Q.S.
Layer 2 (tooth side):
INGREDIENT %w/w
Potassium silicate 1.0
SiO2 2.5
HPC 90.0
Water Q.S.
Example 9: Illustrates a film forming paste. In this Example Carbopol was dispersed in the ethanol. Glycerol was added and mixture stirred until material thickens. Ethocel was added. A second mixture was prepared containing the molten petrolatum, PEG 400, clove oil and the silica dispersed in the mixture. To the petrolatum silica dispersion was added the ethocel mixture with stirring. And blend thoroughly until mixture was homogeneous. Cooled gel was packed into tubes. This material sticks readily to wet surfaces.
INGREDIENT %w/w
Petrolatum 22.0
Sident 22 5.00
Carbopol 974P 3.00
Clove oil 1.00
Ethocel St- 10 10.0
Ethanol 30.0
Glycerol 20.0
PEG 400 10.0 Example 10: Illustrates a film forming gel. Ethyl cellulose was dispersed in the ethanol. A second mixture containing the molten petrolatum, mineral oil, clove oil and the silica dispersed therein, was prepared. To the petrolatum silica dispersion was added the ethocel mixture with stirring. The mixture was blended thoroughly until it was homogeneous. This mixture can be packed in tubes or pen applicators and spread on teeth with a finger or brush.
INGREDIENT %>w/w
Petrolatum 10.0
Sident 22 10.0
Mineral oil 20.0
Clove oil 1.00
Ethocel St- 10 10.0
Gantrez M955 14.0
Ethanol 35.0
Example 11: Illustrates a film forming spray. Ethyl cellulose was dispersed in the ethanol and triethyl citrate. A second mixture was prepared containing the molten petrolatum, mineral oil and clove oil and the silica dispersed in it. To the petrolatum mixture was added the ethyl cellulose mixture with stirring. This mixture was blended thoroughly until mixture was homogeneous. The mixture can be sprayed onto wet surfaces from a pump spray.
INGREDIENT %w/w
Petrolatum 20.0
Mineral oil 15.0
Clove oil 1.00
Ethocel St- 10 10.0
Triethyl citrate 2.00
Ethanol 53.0
All publications, including, but not limited to, patents and patent applications cited in this specification, are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth. The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration it is believed that one skilled in the art can, given the preceding description, utilize the present invention to its fullest extent. Therefore any examples are to be construed as merely illustrative and not a limitation on the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.

Claims

What is claimed is:
1. A controlled-dissolution oral care composition for adherence to natural teeth and adjacent soft tissue comprising at least one water-swellable or water-soluble polymer, which composition creates a physical barrier to painful stimuli associated with dentinal hypersensitivity.
2. The controlled-dissolution oral care composition according to claim 1, wherein the polymer is selected from, cellulose derivatives, polyethylene oxide, chitosan, starch, alginic acid and salts thereof, alkali metal salts of alkylvinylether/maleic acid or anhydride copolymer, and mixtures thereof.
3. A controlled-dissolution oral care composition for adherence to natural teeth and adjacent soft tissue comprising at least one water-swellable or water-soluble polymer and a nerve desensitizing agent, which composition creates a physical barrier to painful stimuli associated with dentinal hypersensitivity.
4. The controlled-dissolution oral care composition of claim 3, wherein the nerve desensitizing agent is selected from a potassium salt, a strontium salt, or a combination of zinc or strontium ions, and mixtures thereof.
5. A controlled-dissolution oral care composition for adherence to natural teeth and adjacent soft tissue comprising at least one water-swellable or water-soluble polymer and a mineralizing agent, which composition creates a physical barrier to painful stimuli associated with dentinal hypersensitivity.
6. The controlled-dissolution oral care composition of claim 5, wherein the mineralizing agent is selected from a soluble calcium source in combination with a soluble phosphate source to produce calcium phosphate, a calcium releasing substrate, hydroxyapatite, arginine carbonate or bioactive glass.
7. A controlled-dissolution oral care composition for adherence to natural teeth and adjacent soft tissue comprising at least one water-swellable or water-soluble polymer and an agent capable of forming a non-mineral precipitate for occluding dentinal tubules, which composition creates a physical barrier to painful stimuli associated with dentinal hypersensitivity.
8. The controlled-dissolution oral care composition according to claim
7, wherein the agent capable of forming a non-mineral precipitate is selected from an inorganic tubule occluder or a polymer tubule occluder.
9. The controlled-dissolution oral care composition according to claim 8, wherein the polymer tubule occluder is selected from sodium alginate, octadecene/maleic anhydride copolymer, polyacrylic acid or chitosan.
10. A composition as claimed in any of the preceeding claims wherein the composition is in the form of a patch, a spray, a gel, a stick or a paste.
11. A method of treating and/or preventing tooth hypersensitivity by applying a composition according to any of the preceeding claims to the tooth surface.
PCT/US2003/036491 2002-11-14 2003-11-14 Controlled-dissolving polymeric device for the oral cavity WO2004045446A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2004553706A JP2006506436A (en) 2002-11-14 2003-11-14 Oral dissolution controllable polymer device
EP03783508A EP1575444A1 (en) 2002-11-14 2003-11-14 Controlled-dissolving polymeric device for the oral cavity
AU2003290923A AU2003290923A1 (en) 2002-11-14 2003-11-14 Controlled-dissolving polymeric device for the oral cavity
BR0316236-2A BR0316236A (en) 2002-11-14 2003-11-14 Controlled dissolution polymeric device for oral cavity
CA002505889A CA2505889A1 (en) 2002-11-14 2003-11-14 Controlled-dissolving polymeric device for the oral cavity
MXPA05005153A MXPA05005153A (en) 2002-11-14 2003-11-14 Controlled-dissolving polymeric device for the oral cavity.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42646902P 2002-11-14 2002-11-14
US60/426,469 2002-11-14

Publications (1)

Publication Number Publication Date
WO2004045446A1 true WO2004045446A1 (en) 2004-06-03

Family

ID=32326360

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/036491 WO2004045446A1 (en) 2002-11-14 2003-11-14 Controlled-dissolving polymeric device for the oral cavity

Country Status (7)

Country Link
EP (1) EP1575444A1 (en)
JP (1) JP2006506436A (en)
AU (1) AU2003290923A1 (en)
BR (1) BR0316236A (en)
CA (1) CA2505889A1 (en)
MX (1) MXPA05005153A (en)
WO (1) WO2004045446A1 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007076444A3 (en) * 2005-12-21 2007-08-16 Colgate Palmolive Co Improved oral compositions comprising zinc citrate and/or tocopherol agents
US20120020899A1 (en) * 2009-04-01 2012-01-26 Colgate-Palmolive Company Oral compositions for treating tooth sensitivity and methods of use and manufacture thereof
WO2012130863A3 (en) * 2011-03-30 2013-01-17 Glaxo Group Limited Novel composition
CN103153267A (en) * 2010-08-18 2013-06-12 高露洁-棕榄公司 Oral care product and methods of use and manufacture thereof
JP2013216682A (en) * 2006-02-13 2013-10-24 Akzo Nobel Nv Film and film-forming composition
WO2015076777A1 (en) * 2013-11-19 2015-05-28 Colgate-Palmolive Company Tooth varnish compositions and methods for their use
EP2335669A4 (en) * 2008-10-08 2016-05-11 Univ Seoul Nat R & Db Found Composition for tooth desensitizer
US9370479B2 (en) 2011-02-18 2016-06-21 Gaba International Holding Ag Mouthrinse composition
CN107569395A (en) * 2017-09-04 2018-01-12 天津医科大学口腔医院 It is a kind of to make the material of desensitizing dental for closing dentinal tubule
CN107743387A (en) * 2015-06-05 2018-02-27 荷兰联合利华有限公司 Oral care appliance
US9918918B2 (en) 2008-02-08 2018-03-20 Colgate-Palmolive Company Compositions for tooth-whitening comprising a bleaching agent and a basic amino acid, and methods and devices for application thereof
US9968803B2 (en) 2009-10-29 2018-05-15 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy
IL259238A (en) * 2015-11-20 2018-07-31 Colgate Palmolive Co Oral care composition comprising chitosan and silica
EP2252254B1 (en) * 2008-02-08 2018-08-08 Colgate-Palmolive Company Use of a basic amino acid in a device used in oral care
US10595976B2 (en) 2015-06-05 2020-03-24 Conopco Inc. Oral care device
US10653605B2 (en) 2011-02-18 2020-05-19 Gaba International Holding Gmbh Dentifrice composition
CN115337247A (en) * 2022-07-21 2022-11-15 安徽中医药大学 Propolis volatile oil coating and preparation method of toothpaste prepared from same

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0714868A2 (en) * 2006-09-01 2013-05-28 Smithkline Beecham Corp denture treatment composition
CA2705606C (en) * 2008-02-08 2014-07-08 Colgate-Palmolive Company Compositions and methods comprising basic amino acid peptides and proteases
US9320699B2 (en) * 2010-03-31 2016-04-26 Colgate-Palmolive Company Oral care composition
KR101569348B1 (en) * 2012-01-13 2015-11-27 (주)아모레퍼시픽 Oral composition for sensitive teeth
JP5653550B1 (en) * 2014-05-30 2015-01-14 株式会社松風 Neutralization promoting ion sustained release dental film
MX2020011410A (en) * 2018-05-14 2021-09-01 Procter & Gamble Foaming oral care compositions.
US11911492B2 (en) 2018-05-14 2024-02-27 The Procter & Gamble Company Oral care compositions comprising metal ions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334375A (en) * 1988-12-29 1994-08-02 Colgate Palmolive Company Antibacterial antiplaque oral composition
US5849266A (en) * 1989-01-31 1998-12-15 Perio Products Ltd. Dental composition for hypersensitive teeth

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334375A (en) * 1988-12-29 1994-08-02 Colgate Palmolive Company Antibacterial antiplaque oral composition
US5849266A (en) * 1989-01-31 1998-12-15 Perio Products Ltd. Dental composition for hypersensitive teeth

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1962778B1 (en) 2005-12-21 2017-08-23 Colgate-Palmolive Company Improved oral compositions comprising zinc citrate
AU2006330508B2 (en) * 2005-12-21 2010-02-25 Colgate-Palmolive Company Improved oral compositions comprising zinc citrate and/or tocopherol agents
CN104127399A (en) * 2005-12-21 2014-11-05 高露洁-棕榄公司 Improved oral compositions comprising zinc citrate and/or tocopherol agents
WO2007076444A3 (en) * 2005-12-21 2007-08-16 Colgate Palmolive Co Improved oral compositions comprising zinc citrate and/or tocopherol agents
JP2013216682A (en) * 2006-02-13 2013-10-24 Akzo Nobel Nv Film and film-forming composition
EP2252254B1 (en) * 2008-02-08 2018-08-08 Colgate-Palmolive Company Use of a basic amino acid in a device used in oral care
US9918918B2 (en) 2008-02-08 2018-03-20 Colgate-Palmolive Company Compositions for tooth-whitening comprising a bleaching agent and a basic amino acid, and methods and devices for application thereof
US10130597B2 (en) 2008-02-08 2018-11-20 Colgate-Palmolive Company Compositions and devices
EP2335669A4 (en) * 2008-10-08 2016-05-11 Univ Seoul Nat R & Db Found Composition for tooth desensitizer
US20120020899A1 (en) * 2009-04-01 2012-01-26 Colgate-Palmolive Company Oral compositions for treating tooth sensitivity and methods of use and manufacture thereof
US10682532B2 (en) 2009-10-29 2020-06-16 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy
US9968803B2 (en) 2009-10-29 2018-05-15 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy
US10668306B2 (en) 2009-10-29 2020-06-02 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy
US11147992B2 (en) 2009-10-29 2021-10-19 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy
US11285342B2 (en) 2009-10-29 2022-03-29 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy
CN103153267A (en) * 2010-08-18 2013-06-12 高露洁-棕榄公司 Oral care product and methods of use and manufacture thereof
US9370479B2 (en) 2011-02-18 2016-06-21 Gaba International Holding Ag Mouthrinse composition
US10653605B2 (en) 2011-02-18 2020-05-19 Gaba International Holding Gmbh Dentifrice composition
AU2012234273B2 (en) * 2011-03-30 2016-04-21 Glaxo Group Limited Novel composition
US9839597B2 (en) 2011-03-30 2017-12-12 Glaxo Group Limited Combating dentine hypersensitivity with a non-ionic polymer
WO2012130863A3 (en) * 2011-03-30 2013-01-17 Glaxo Group Limited Novel composition
WO2015076777A1 (en) * 2013-11-19 2015-05-28 Colgate-Palmolive Company Tooth varnish compositions and methods for their use
RU2648510C1 (en) * 2013-11-19 2018-03-26 Колгейт-Палмолив Компани, Сша Dental lacquer compositions and methods of their use
US9833392B2 (en) 2013-11-19 2017-12-05 Colgate-Palmolive Company Tooth varnish compositions and methods for their use
CN107743387A (en) * 2015-06-05 2018-02-27 荷兰联合利华有限公司 Oral care appliance
US10595976B2 (en) 2015-06-05 2020-03-24 Conopco Inc. Oral care device
US20180125625A1 (en) * 2015-06-05 2018-05-10 Conopco, Inc., D/B/A Unilever Oral care device
IL259238A (en) * 2015-11-20 2018-07-31 Colgate Palmolive Co Oral care composition comprising chitosan and silica
US20180325799A1 (en) * 2015-11-20 2018-11-15 Colgate-Palmolive Company Oral Care Composition Comprising Chitosan and Silica
CN107569395A (en) * 2017-09-04 2018-01-12 天津医科大学口腔医院 It is a kind of to make the material of desensitizing dental for closing dentinal tubule
CN107569395B (en) * 2017-09-04 2020-08-11 天津医科大学口腔医院 Material for closing dentinal tubules to desensitize teeth
CN115337247A (en) * 2022-07-21 2022-11-15 安徽中医药大学 Propolis volatile oil coating and preparation method of toothpaste prepared from same
CN115337247B (en) * 2022-07-21 2023-12-22 安徽中医药大学 Propolis volatile oil coating and preparation method of toothpaste prepared from propolis volatile oil coating

Also Published As

Publication number Publication date
BR0316236A (en) 2005-10-04
JP2006506436A (en) 2006-02-23
EP1575444A1 (en) 2005-09-21
MXPA05005153A (en) 2005-07-22
AU2003290923A1 (en) 2004-06-15
CA2505889A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
WO2004045446A1 (en) Controlled-dissolving polymeric device for the oral cavity
JP2821967B2 (en) Composition for relieving and removing tooth hypersensitivity
US5849266A (en) Dental composition for hypersensitive teeth
US20030215401A1 (en) Dental composition for hypersensitve teeth
RU2440809C2 (en) Controlled superficial gel-generation of mucoadhesive polymers in oral cavity mucosa
EP1863438B1 (en) Tooth whitener
JPH05503280A (en) Topical preparations for the treatment of conditions of teeth and their supporting tissues
US20070059257A1 (en) Dentinal composition for hypersensitive teeth
CA2550537A1 (en) Oral care compositions, devices, and methods of using the same
EP2249764B1 (en) Tooth sealant
KR20210024080A (en) Oral composition and mucoadhesive thin film formed therefrom
EP2056787B2 (en) Denture care composition
JP4828025B2 (en) Stannous fluoride composition for the treatment of dental hypersensitivity
US20020041852A1 (en) Dental composition for hypersensitive teeth
EP0381445B1 (en) Dental composition for hypersensitive teeth
Ahmad et al. Dental therapeutic systems
KR101154935B1 (en) Liquid-crystal type tooth whitener
US20120134936A1 (en) Tooth Whitener
Negm et al. Reaction of the exposed pulps to new cements containing calcium hydroxide
KR20170091988A (en) Mouth band
JP5891176B2 (en) Composition comprising an alginate having a high guluronic acid / mannuronic acid ratio for use in the treatment of dentine hypersensitivity
KR100308247B1 (en) Compositions for cleaning oral cavity
CA2544624C (en) Tooth-whitening composition
JP2003212743A (en) Composition for oral cavity for hyperesthesia
KR20170099645A (en) Oral composition for relieving sensitive teeth

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AU BA BB BR BZ CA CN CO CR CU DM DZ EC EG GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ OM PH PL RO SC SG TN TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003290923

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2505889

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004553706

Country of ref document: JP

Ref document number: PA/A/2005/005153

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003783508

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003783508

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0316236

Country of ref document: BR